$type=grid$count=4$tbg=rainbow$meta=0$snip=0$rm=0

Top of Post

Thrombocytopenia Treatment Market - Opportunity Analysis, 2018-2026



Thrombocytopenia is a disorder in which a patient has low level of platelets in the blood. The major causes of thrombocytopenia are inefficient production of platelets, platelet splenic sequestration,...
Thrombocytopenia is a disorder in which a patient has low level of platelets in the blood. The major causes of thrombocytopenia are inefficient production of platelets, platelet splenic sequestration, and accelerative destruction of platelets. The most common ineffective production of thrombocytes are due bone marrow failure syndrome such as myelodysplastic syndrome and aplastic anemia. Thrombocytopenia can be inherited or acquired. In 2014, According to a research article published in Professional Med J, 2014, entitled Frequency of Thrombocytopenia, the frequency of thrombocytopenia is higher for people aged 60 years and above, suffering from non-cirrhotic liver disease. However, rampant discovery coupled with the ability to clone thrombopoietin has resulted in new treatment opportunities for clinical manifestation.

Click To Continue Reading on Thrombocytopenia Treatment Market


More specific treatment plans usually depend on the underlying etiology of thrombocytopenia. In most cases the underlying cause of thrombocytopenia is not known, especially in the case of severe bleeding. In September 2015, Lusutrombopag, an orally bioavailable, small molecule thrombopoietin (TPO) receptor agonist developed by Shionogi Inc., received approval by Pharmaceuticals and Medical Devices Agency of Japan. Lusutrombopag helped enhance chronic liver disease (CLD) associated with thrombocytopenia for patients scheduled to undergo invasive procedures.

Lusustrombopag acts specifically on human thrombopoietin (TPO) receptors and stimulates signaling pathways that trigger the proliferation and differentiation of bone marrow cells into megakaryocytes. Thus, increasing the blood platelet count. However, patients treated with Lusustrombopag further showed higher counts of blood leukocytes and erythrocyte. Furthermore, in June 2017, FDA accepted application for new oral investigational drug, Tavalisse (fostamatinib disodium), by Rigel Pharmaceuticals, Inc. This drug is designed to inhibit the spleen tyrosine kinase and treat patients suffering from chronic or persistent immune thrombocytopenia. 

Request Sample Copy of this Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/1484

Key Vendors:

3SBio Inc., Amarillo Biosciences, Inc., Amgen Inc., Baxalta Incorporated, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cellerant Therapeutics, Inc., Eisai Co., Ltd., Hansa Medical AB, Intas Pharmaceuticals Ltd., Merck & Co., Inc., Momenta Pharmaceuticals, Inc., Myelo Therapeutics GmbH, Neumedicines Inc., Novartis AG, Pfizer Inc., Prophylix Pharma AS, Rigel Pharmaceuticals, Inc., Shionogi & Co., Ltd., STATegics, Inc., and ViroMed Co., Ltd.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
SeattleFeature Articles, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Visit our news Website: https://www.coherenttimes.org/

COMMENTS

Name

Animal,32,Autos,39,Career,1000,Celebrity,89,Finance,283,Food,148,Health,402,Juicy,1348,Lifestyle,659,Love,15,Men's,29,Pets,149,Technology,174,Travel,178,Women's,37,
ltr
item
eZine Insider: Thrombocytopenia Treatment Market - Opportunity Analysis, 2018-2026
Thrombocytopenia Treatment Market - Opportunity Analysis, 2018-2026
https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjav6JHlGsWuo8jlq0C0q_FSWvagA-5WA6LJQHUy9ojMekKYefb5Q3L_WlrNAN2KNlEn9Qutct9QZZnzPMfhlzJ9n_5dALJf43TMIWvWFRKI9QjWb6WfFwZzjbDc35XDOGAyMgL-IPtHnk/s1600/Home-Healthcare-Software-Market.png
https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjav6JHlGsWuo8jlq0C0q_FSWvagA-5WA6LJQHUy9ojMekKYefb5Q3L_WlrNAN2KNlEn9Qutct9QZZnzPMfhlzJ9n_5dALJf43TMIWvWFRKI9QjWb6WfFwZzjbDc35XDOGAyMgL-IPtHnk/s72-c/Home-Healthcare-Software-Market.png
eZine Insider
https://www.ezineinsider.com/2019/03/thrombocytopenia-treatment-market.html
https://www.ezineinsider.com/
https://www.ezineinsider.com/
https://www.ezineinsider.com/2019/03/thrombocytopenia-treatment-market.html
true
4382479518559370816
UTF-8
Loaded All Posts Not found any posts VIEW ALL Read More Reply Cancel reply Delete By Home PAGES POSTS View All RECOMMENDED FOR YOU LABEL ARCHIVE SEARCH ALL POSTS Not found any post match with your request Back Home Sunday Monday Tuesday Wednesday Thursday Friday Saturday Sun Mon Tue Wed Thu Fri Sat January February March April May June July August September October November December Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec just now 1 minute ago $$1$$ minutes ago 1 hour ago $$1$$ hours ago Yesterday $$1$$ days ago $$1$$ weeks ago more than 5 weeks ago Followers Follow THIS PREMIUM CONTENT IS LOCKED STEP 1: Share to a social network STEP 2: Click the link on your social network Copy All Code Select All Code All codes were copied to your clipboard Can not copy the codes / texts, please press [CTRL]+[C] (or CMD+C with Mac) to copy